Physician profile
Bret E Sherman
NPI 1386604536
$3,685.71
in general payments reported to CMS, 2019-2025
20 companies · $61.23 in 2025
The $61.23 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $335 · 2021: $624 · 2022: $898 · 2023: $620 · 2024: $656 · 2025: $61.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,271.82 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $937.49 | 2019-2024 | Xolair |
| Astrazeneca Pharmaceuticals LP | $472.84 | 2019-2024 | Tezspire, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $243.19 | 2019-2022 | |
| Optinose US, INC. | $130.18 | 2021 | |
| Genzyme Corporation | $94.32 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $87.40 | 2020-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $86.19 | 2021-2024 | Takhzyro |
| Alk-Abello, INC | $68.30 | 2021-2024 | Grastek, Odactra |
| Carestream Dental, LLC | $58.96 | 2019 | |
| Biocryst US Sales Co., LLC | $41.09 | 2023-2024 | Orladeyo |
| Kaleo, INC. | $39.76 | 2020-2021 | |
| Phadia US INC. | $29.02 | 2020-2022 | |
| Pharming Healthcare, INC. | $22.02 | 2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $21.24 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $19.82 | 2023 | Inspire |
| Csl Behring | $18.73 | 2023 | Hizentra |
| Abbvie INC. | $15.85 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.59 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.